Acrux Secures $0.55m Advance on FY26 R&D Tax Incentive to Support HRT Development

Acrux ( (AU:ACR) ) just unveiled an announcement.

Acrux Limited has secured a second advance of $0.55 million against its FY26 R&D Tax Incentive from Radium Capital, covering eligible R&D conducted between 1 October 2025 and 28 February 2026. The funding represents about 80% of the estimated rebate for that four-month period and is obtained through a short-term facility that provides earlier access to tax incentive cash flows, improving alignment with spending.

Following confirmation from the U.S. Food and Drug Administration on the regulatory pathway for Acrux’s Hormone Replacement Therapy program, the company plans to use the funds to support development of its HRT pipeline and manage working capital needs. The terms of this advance are unchanged from the prior FY26 drawdown, underscoring a consistent funding approach that helps sustain R&D momentum and operational flexibility while Acrux progresses key topical pharmaceutical products toward commercialisation.

The most recent analyst rating on (AU:ACR) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Acrux stock, see the AU:ACR Stock Forecast page.

More about Acrux

Acrux Limited is a Melbourne-based specialty pharma company focused on developing and commercialising topically applied pharmaceutical products. Leveraging 25 years of experience, it has brought multiple products to market through licensees, with a particular emphasis on the United States, highlighting its expertise in transdermal drug delivery and international partnering.

Average Trading Volume: 275,539

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$5.54M

For detailed information about ACR stock, go to TipRanks’ Stock Analysis page.